Cargando…

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

Poly (ADP-ribose) polymerase (PARP)-inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for BRCA-deficient tumors and also show efficacy in platinum-sensitive tumors. However, resistance to PARPi occurs in numerous patients and in particular acquired PARPi resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedier, André, Maggi, Nadia, Tozzi, Alessandra, Disler, Muriel, Coelho, Ricardo, Jacob, Francis, Heinzelmann-Schwarz, Viola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170353/
https://www.ncbi.nlm.nih.gov/pubmed/35642662
http://dx.doi.org/10.3892/ijo.2022.5379
_version_ 1784721405233856512
author Fedier, André
Maggi, Nadia
Tozzi, Alessandra
Disler, Muriel
Coelho, Ricardo
Jacob, Francis
Heinzelmann-Schwarz, Viola
author_facet Fedier, André
Maggi, Nadia
Tozzi, Alessandra
Disler, Muriel
Coelho, Ricardo
Jacob, Francis
Heinzelmann-Schwarz, Viola
author_sort Fedier, André
collection PubMed
description Poly (ADP-ribose) polymerase (PARP)-inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for BRCA-deficient tumors and also show efficacy in platinum-sensitive tumors. However, resistance to PARPi occurs in numerous patients and in particular acquired PARPi resistance presents a major obstacle in the treatment of these tumors. In the present study, it was investigated whether stepwise exposure of ovarian cancer cells to escalating concentrations of olaparib produced subcells with acquired resistance to PARPi and/or acquired cross-resistance to platinum compounds, paclitaxel, and doxorubicin. To this aim, the sensitivity of fourteen ovarian cancer cell lines, including nine with TP53-mutations and five carrying BRCA-mutations, to olaparib and niraparib was determined and a subset of seven cell lines was selected to investigate the potential of olaparib to produce resistance. It was identified that escalating olaparib did neither produce subcells with acquired PARPi-resistance nor did it produce acquired cross-resistance to platinum compounds, doxorubicin, and paclitaxel. This finding was independent of the cells' TP53 and BRCA mutation status. CRISPR-Cas9 mediated deletion of PARP1 did not affect sensitivity to PARPi, platinum compounds, doxorubicin, and paclitaxel. In addition, olaparib sensitivity correlated with niraparib sensitivity, but BRCA-mutated cells were not more sensitive to PARPi. Moreover, PARPi sensitivity associated with cross-sensitivity not only to platinum compounds but also to anthracylines, paclitaxel, and inhibitors of histone deacetylases. These in vitro data indicated that olaparib exposure is unlikely to produce an acquired resistance phenotype and that PARPi-sensitive ovarian cancer cells are also cross-sensitive to non-platinum and even to compounds not directly interacting with the DNA.
format Online
Article
Text
id pubmed-9170353
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-91703532022-06-12 Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines Fedier, André Maggi, Nadia Tozzi, Alessandra Disler, Muriel Coelho, Ricardo Jacob, Francis Heinzelmann-Schwarz, Viola Int J Oncol Articles Poly (ADP-ribose) polymerase (PARP)-inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for BRCA-deficient tumors and also show efficacy in platinum-sensitive tumors. However, resistance to PARPi occurs in numerous patients and in particular acquired PARPi resistance presents a major obstacle in the treatment of these tumors. In the present study, it was investigated whether stepwise exposure of ovarian cancer cells to escalating concentrations of olaparib produced subcells with acquired resistance to PARPi and/or acquired cross-resistance to platinum compounds, paclitaxel, and doxorubicin. To this aim, the sensitivity of fourteen ovarian cancer cell lines, including nine with TP53-mutations and five carrying BRCA-mutations, to olaparib and niraparib was determined and a subset of seven cell lines was selected to investigate the potential of olaparib to produce resistance. It was identified that escalating olaparib did neither produce subcells with acquired PARPi-resistance nor did it produce acquired cross-resistance to platinum compounds, doxorubicin, and paclitaxel. This finding was independent of the cells' TP53 and BRCA mutation status. CRISPR-Cas9 mediated deletion of PARP1 did not affect sensitivity to PARPi, platinum compounds, doxorubicin, and paclitaxel. In addition, olaparib sensitivity correlated with niraparib sensitivity, but BRCA-mutated cells were not more sensitive to PARPi. Moreover, PARPi sensitivity associated with cross-sensitivity not only to platinum compounds but also to anthracylines, paclitaxel, and inhibitors of histone deacetylases. These in vitro data indicated that olaparib exposure is unlikely to produce an acquired resistance phenotype and that PARPi-sensitive ovarian cancer cells are also cross-sensitive to non-platinum and even to compounds not directly interacting with the DNA. D.A. Spandidos 2022-06-01 /pmc/articles/PMC9170353/ /pubmed/35642662 http://dx.doi.org/10.3892/ijo.2022.5379 Text en Copyright: © Fedier et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Fedier, André
Maggi, Nadia
Tozzi, Alessandra
Disler, Muriel
Coelho, Ricardo
Jacob, Francis
Heinzelmann-Schwarz, Viola
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
title Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
title_full Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
title_fullStr Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
title_full_unstemmed Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
title_short Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
title_sort exposure to escalating olaparib does not induce acquired resistance to parpi and to other chemotherapeutic compounds in ovarian cancer cell lines
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170353/
https://www.ncbi.nlm.nih.gov/pubmed/35642662
http://dx.doi.org/10.3892/ijo.2022.5379
work_keys_str_mv AT fedierandre exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines
AT magginadia exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines
AT tozzialessandra exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines
AT dislermuriel exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines
AT coelhoricardo exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines
AT jacobfrancis exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines
AT heinzelmannschwarzviola exposuretoescalatingolaparibdoesnotinduceacquiredresistancetoparpiandtootherchemotherapeuticcompoundsinovariancancercelllines